Search the Newsreel

ENvue Medical, Inc. SEC Filing (Aug 14, 2026)

ENvue Medical, Inc. has filed a Form 12b-25 Notification of Late Filing for its Quarterly Report on Form 10-Q for the period ended June 30, 2026. The company stated that additional time is needed to prepare, compile, and analyze supporting documentation to complete its …

ICL Group (ICL) Earnings Beat Brings Its Valuation Back Into Focus

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. ICL Group (NYSE:ICL) is back in focus after reporting second quarter 2026 sales of …

Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax

Supernus Pharmaceuticals' Chief Medical Officer, Jonathan Rubin, exercised 750 Performance Share Units (PSUs) on August 12, 2026, converting them into 750 shares of common stock. To cover tax withholding requirements associated with this vesting, 363 shares were withheld by the company at a price …

Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate

Investment entities affiliated with Samsara BioCapital and Srinivas Akkaraju have reported significant beneficial ownership in Eloxx Pharmaceuticals (ELOX). Dr. Srinivas Akkaraju holds 9.99% of the common stock, while each Samsara BioCapital-affiliated entity owns 5.0%. This includes common shares and Pre-Funded Warrants subject to a …

Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have collectively reported an 8.1% beneficial ownership stake in X4 Pharmaceuticals, Inc. This disclosure was made via an amended Schedule 13G filing, indicating shared voting and dispositive power over 8,085,006 shares, including …

Fuller & Thaler (NASDAQ: COLL) reports 5.03% beneficial stake in common stock

Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership of 5.03% in COLLEGIUM PHARMACEUTICAL, INC (COLL) common stock, totaling 1,632,780.71 shares as of June 30, 2026. The firm holds sole voting and dispositive power over these shares, which are held in accounts …

Fuller & Thaler boosts disclosure of 5.19% ICU Medical (ICUI) ownership stake

Fuller & Thaler Asset Management, Inc. has filed an amended Schedule 13G, disclosing a 5.19% beneficial ownership stake in ICU Medical (ICUI). The firm holds 1,298,126.96 shares, with sole voting power over 1,276,819.96 shares and sole dispositive power over all 1,298,126.96 shares. The filing, …

Adagio Medical Holdings Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Adagio Medical Holdings (ADGM) received a Nasdaq deficiency notice on August 13, 2026, for failing to meet the Listing Rule 5550(b)(1) requirement of at least $2.5 million in stockholders' equity, as their June 30, 2026 Form 10-Q reported equity of $(415,000). The notice does …

Two Seas Capital (CLMT) discloses 7.5% Calumet stake via Two Seas Global Fund

Two Seas Capital LP, along with its affiliates, has reported a beneficial ownership of 7.5% in Calumet, Inc. (CLMT) through its Schedule 13G/A filing. This stake, totaling 6,619,708 shares of common stock, is held by Two Seas Global (Master) Fund LP. The filing indicates …

Vertical Aerospace (NYSE:EVTL) Releases Quarterly Earnings Results, Meets Expectations

Phio Pharmaceuticals Corp. SEC Filing (Aug 14, 2026)

This article reports on an SEC filing (Form ARS) by Phio Pharmaceuticals Corp. (PHIO) on August 14, 2026. The filing has a low impact and neutral sentiment, and the document is available as a PDF. The article also provides recent news and other SEC …

Air Products & Chemicals Inc. stock outperforms competitors on strong trading day

Shares of Air Products & Chemicals Inc. (APD) rose 1.13% to $308.97 on Friday, outperforming the broader market, which saw the S&P 500 Index and Dow Jones Industrial Average fall. This marked the stock's second consecutive day of gains despite a grim trading session …

IceCure Medical (ICCM) expands 2024 employee share incentive reserve

IceCure Medical Ltd. has increased the ordinary shares reserved for its 2024 Employee Equity Incentive Plan by 2,500,000, bringing the new total to 2,612,667 ordinary shares. This expansion, approved by the board on August 11, 2026, provides additional capacity for future equity awards to …

Crosslink Capital (IIIV) reports 5.7% beneficial stake in i3 Verticals Class A

Crosslink Capital, Inc. and Michael J. Stark have reported a beneficial ownership of 5.7% in i3 Verticals, Inc. Class A common stock, totaling 1,117,986 shares. This stake, held by funds advised by Crosslink, includes shared voting and dispositive power for all reported shares. The …

RA Capital discloses 6.2% BioCryst (BCRX) holding of 15.8M shares

RA Capital Management, L.P. and its affiliated entities have reported a passive ownership stake of 6.2% in BioCryst Pharmaceuticals, Inc. This holding, as of June 30, 2026, comprises 15,827,186 shares of common stock, with RA Capital Healthcare Fund, L.P. directly owning these shares. The …

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress

Citius Pharmaceuticals reported strong Q3 2026 financial results, including $7.1 million in commercial sales revenue for the first nine months of the fiscal year and $17 million in cash reserves. The company highlighted significant progress with its lead product, LYMPHIR, noting an 86% objective …

ADAR1 group discloses 9.9% Kiora Pharmaceuticals (KPRX) stake via shares and warrants

ADAR1 Capital Management, along with ADAR1 Capital Management GP, LLC and Daniel Schneeberger, have reported a beneficial ownership of 9.9% in Kiora Pharmaceuticals (KPRX). This stake, detailed in an amended passive investment disclosure (SCHEDULE 13G/A), includes common shares and shares underlying pre-funded and milestone …

Nantahala Capital discloses 9.99% Kiora Pharmaceuticals (KPRX) stake via 13G/A filing

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 9.99% in Kiora Pharmaceuticals, Inc. (KPRX) through a Schedule 13G/A filing. As of June 30, 2026, they beneficially own 491,889 shares, including those acquirable through convertible …

Mobia Medical (MOBI) gets 11.1% ownership filing from Green Park & Golf group

Green Park & Golf Ventures II, LLC and affiliated entities have reported a beneficial ownership of 11.1% in Mobia Medical, Inc. (MOBI), totaling 3,684,409 shares. This stake is held across numerous LLCs, with managers Clay M. Heighten, MD, Carl D. Soderstrom, and Gilbert G. …

Callan JMB (CJMB) posts deeper 2026 losses and taps equity line for cash

Callan JMB Inc. (CJMB) reported increased losses and reduced revenue for the three and six months ended June 30, 2026, primarily due to decreased demand for its emergency preparedness services. The company's net loss widened significantly, and its cash position declined, leading management to …

Nantahala Capital discloses 9.91% Eloxx Pharmaceuticals (ELOX) ownership in Schedule 13G

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reported a 9.91% beneficial ownership stake in Eloxx Pharmaceuticals, Inc. (ELOX) through a Schedule 13G filing. As of June 30, 2026, the reporting persons beneficially own 400,000 shares, with shared voting and …

Van Eck Associates (SMR) discloses 8.5% NuScale Power stake via ETF holdings

Van Eck Associates Corporation has disclosed an 8.5% beneficial ownership stake in NuScale Power Corp Class A ordinary shares, totaling 29,311,762 shares, through an amendment to its SCHEDULE 13G filing. The firm holds sole voting and dispositive power over these shares. A significant portion, …

Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Vertex Pharmaceuticals Inc. (VRTX) stock fell 2.07% on Friday, closing at $505.75, amid a general market decline where the S&P 500 and Dow Jones Industrial Average also saw losses. This marked the third consecutive day of losses for the company's shares.

Intuitive Surgical (ISRG) Is Facing Fresh Competition In U.S. Surgical Robotics

Intuitive Surgical (ISRG) is facing new competition in the U.S. surgical robotics market as Johnson & Johnson's Ottava system received FDA authorization. Ottava's space-saving design and integration with J&J's existing surgical tools pose a direct challenge to Intuitive Surgical's da Vinci systems, potentially impacting …

NRx Pharmaceuticals (NRXP) grows clinic revenue, flags going concern risk

NRx Pharmaceuticals reported its Q2 2026 results, showing significant growth in net patient service revenue to $1.1 million for the quarter and $2.2 million for the first six months, primarily through its HOPE subsidiary's acquired Florida behavioral health clinics. Despite this new revenue stream …

Lexicon Pharmaceuticals (LXRX) Completes Phase III Enrollment, Is The 38% Undervaluation Case Convincing?

LB Pharmaceuticals (LBRX) investor group reports 5.0% beneficial stake in 13G/A

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have reported a beneficial ownership of 5.0% in LB Pharmaceuticals Inc. (LBRX), totaling 1,447,310 shares, through an amended Schedule 13G filing. This ownership percentage is based on 28,676,652 shares outstanding as …

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

The past couple of years have been volatile for Vertex Pharmaceuticals (NASDAQ: VRTX). Between clinical setbacks and worse-than-expected financial results, the company has sometimes disappointed investors. However, Vertex has always bounced back, and it recently hit a new all-time high, though it has since …

Quoin Q2 Loss Hits $5.37 Million as FDA Clears Peeling Skin IND

Quoin Pharmaceuticals Ltd. (QNRX) reported a net loss of $5.37 million for the second quarter of 2026, an increase from $3.70 million in the prior year. Despite this, the company's cash position is expected to fund operations into 2027. The FDA also conditionally approved …

Processa Pharmaceuticals (NASDAQ: PCSA) lands $183M funding and Vidya BTK acquisition

Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership

Southpoint-related entities and individual John S. Clark have filed an amended Schedule 13G/A for Fennec Pharmaceuticals Inc. (FENC), indicating that they now beneficially own 0 Common Shares, representing 0% of the class. This filing signifies that their ownership is 5 percent or less, with …

Profound Medical CFO Steps Down; Controller Takes Interim Role

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced a management change, with Matthew Sobczyk, formerly Corporate Controller, promoted to Interim Chief Financial Officer. He succeeds Rashed Dewan, who has stepped down but will remain on a short-term consulting contract to ensure a smooth transition. …

Galmed Pharmaceuticals (GLMD) to implement 1-for-8 reverse share split in August 2026

Galmed Pharmaceuticals (GLMD) has announced a 1-for-8 reverse share split, consolidating its ordinary shares, with post-split trading expected to begin on August 19, 2026, on the Nasdaq Capital Market. This action will reduce the number of outstanding shares from 8,332,518 to approximately 1,041,565 and …

Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity

Amneal Pharmaceuticals director John Kiely reported selling 50,000 shares of Class A Common Stock at a weighted average price of $17.64 per share on August 13, 2026. Additionally, he made a charitable donation of 10,000 shares of Class A Common Stock to a donor-advised …

Wasserstein group (CLMT) discloses 4.6% Calumet Inc. ownership in Schedule 13G/A

Wasserstein Management L.P. and its affiliated entities have reported a beneficial ownership of 4.6% in Calumet Inc. (CLMT) common stock, as detailed in an amended Schedule 13G filing on June 30, 2026. This stake amounts to 3,964,893 shares out of 87,147,147 total shares outstanding. …

Intuitive Surgical Inc. stock underperforms Friday when compared to competitors

Intuitive Surgical Inc. (ISRG) shares fell 1.68% to $394.51 on Friday, underperforming the broader market as the S&P 500 and Dow Jones also experienced slight declines. The company's stock closed 34.67% below its 52-week high, which was set on January 7th. This report highlights …